Talk Bio

FDA Grants Accelerated Approval to Stealth BioTherapeutics’ Forzinity, the First Treatment for Barth Syndrome

FDA Approves Stealth BioTherapeutics' Forzinity as First Treatment for Barth Syndrome After Rejection and Delay

Stealth BioTherapeutics Resubmits Third FDA Application for Rare Disease Drug

FDA Rejects Stealth BioTherapeutics' Rare Disease Drug but Leaves Door Open for Accelerated Approval

FDA decision on Stealth's Barth syndrome drug delayed, again